Last reviewed · How we verify

CroFab

Instituto Bioclon S.A. de C.V. · FDA-approved active Biologic

CroFab is a polyclonal antivenom that binds and neutralizes venom toxins from North American crotalid snakes (rattlesnakes, cottonmouths, and copperheads).

CroFab is a polyclonal antivenom that binds and neutralizes venom toxins from North American crotalid snakes (rattlesnakes, cottonmouths, and copperheads). Used for Envenomation by North American crotalid snakes (rattlesnakes, cottonmouths, copperheads).

At a glance

Generic nameCroFab
SponsorInstituto Bioclon S.A. de C.V.
Drug classAntivenom (polyclonal antibody fragments)
TargetCrotalid venom toxins (phospholipase A2, serine proteases, metalloproteinases)
ModalityBiologic
Therapeutic areaToxicology / Emergency Medicine
PhaseFDA-approved

Mechanism of action

CroFab contains immunoglobulin fragments (Fab) derived from sheep immunized with crotalid snake venoms. These Fab fragments bind to and neutralize multiple venom components including phospholipase A2, serine proteases, and metalloproteinases, preventing their pathological effects on coagulation, hemolysis, and tissue damage. The drug is administered intravenously to treat envenomation by North American pit vipers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: